The Carfilzomib Market is projected to witness significant growth over the coming years, driven primarily by the increasing prevalence of multiple myeloma and advancements in targeted cancer therapies. Carfilzomib, a proteasome inhibitor, plays a critical role in treating relapsed and refractory multiple myeloma patients, making it a focal point in oncology therapeutics. According to...